top of page

Pioneers of NexCAR19, India's first indigenous CAR-T cell therapy

T-cell destroys cancer cell digital animation.jpg
T-cell destroys cancer cell digital animation.jpg

ImmunoACT, an IIT-Bombay spin-off incubated at SINE, is India's first gene-modified cell therapy company, fully integrated from R&D to Manufacturing and Commercialization.

Our goal is bringing innovative, affordable and accessible cell & gene therapies to the masses, to improve overall survival outcomes in diseases with a clinically unmet need.


India ranks second in global cancer mortality

Screenshot 2021-08-02 20_edited.png

In B-cell cancers such as Acute Lymphoblastic Leukaemia & Large B-cell Lymphomas, over 40% of patients do not achieve a response to first line therapies or relapse. 

CAR-T Cell Therapies are a revolution in the care of haematological malignancies, showing remarkable improvements in overall & disease-free survival rates.

* Based on inputs from multiple centres in India

CAR-T cells: A fighting chance to achieve remission

Deploying smarter cells to eliminate cancer and autoimmune disorders


Our Technology

We design, develop, and manufacture novel therapies called CARs (Chimeric Antigen Receptors), which are created by modifying a patient's own T-cells by using a vehicle that enables them to better target certain cancers and enhance their anti-tumour activity.

Our CAR-T cell therapies, beginning with NexCAR19 (Talicabtagene autoleucel) are personalized for each patient, and are specifically designed to be more familiar to the human immune system, limiting their side-effects and rendering them safer.

On April 4, 2024, The Hon'ble President of India Smt. Droupadi Murmu Launched and Dedicated NexCAR19, India’s First Indigenous CAR-T cell Therapy to the citizens of the country - as this marked the summit of fully indigenous academic-industry innovation in cell & gene therapies.

What are CAR-T Cell Therapies?


By using a specially designed and patented delivery vehicle called a Lentiviral Vector, T-cells (a set of immune system cells present in our bodies with natural tumour-fighting abilities) are modified - so that they can express proteins which will target specific cancers and enhance their anti-tumour activity against these cancers.

CAR-T Cell Therapies involve training your immune cells to actively and aggressively target known signals on certain types of cancers - and to save these abilities in their memory for future use.

Recoveries are the strongest motivation

Stories from patients who have received NexCAR19 (Talicabtagene autoleucel) in their fight against cancer:

t cell web.png

Stay up-to-date with the latest news and developments from our company with our official newsletter. Each issue is packed with informative articles, exclusive offers, and exciting updates on our products and services. Don’t miss out on the latest happenings

Our Location

1st Floor, Plot R-977, TTC Industrial Area, MIDC Rabale, Navi Mumbai, India – 400701


Contact Number

+91 2248259140

Follow us on

  • X
  • LinkedIn
  • Youtube
bottom of page